| Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia M Quijada-Álamo, M Hernández-Sánchez, C Robledo, ... Journal of hematology & oncology 10, 1-11, 2017 | 51 | 2017 |
| The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia I García-Tuñón, M Hernández-Sánchez, JL Ordoñez, V Alonso-Pérez, ... Oncotarget 8 (16), 26027, 2017 | 43 | 2017 |
| Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia M Forero-Castro, C Robledo, R Benito, I Bodega-Mayor, I Rapado, ... British journal of cancer 117 (2), 256-265, 2017 | 42 | 2017 |
| CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del (11q) CLL cells to dual BCR and PARP inhibition M Quijada-Álamo, M Hernández-Sánchez, V Alonso-Pérez, ... Leukemia 34 (6), 1599-1612, 2020 | 31 | 2020 |
| Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications C Pérez‐Carretero, M Hernández‐Sánchez, T González, ... International Journal of Cancer 147 (10), 2780-2792, 2020 | 30 | 2020 |
| The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment C Pérez-Carretero, I Gonzalez-Gascon-y-Marin, AE Rodriguez-Vicente, ... Diagnostics 11 (5), 853, 2021 | 24 | 2021 |
| CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase M Hernández-Sánchez, J Kotaskova, AE Rodríguez, L Radova, ... Leukemia 33 (2), 518-558, 2019 | 22 | 2019 |
| From biomarkers to models in the changing landscape of chronic lymphocytic leukemia: Evolve or become extinct I González-Gascón-y-Marín, C Muñoz-Novas, AE Rodríguez-Vicente, ... Cancers 13 (8), 1782, 2021 | 20 | 2021 |
| High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia EM Ghia, LZ Rassenti, MY Choi, M Quijada-Álamo, E Chu, GF Widhopf, ... Leukemia 36 (6), 1609-1618, 2022 | 19 | 2022 |
| Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression M Quijada-Álamo, M Hernández-Sánchez, AE Rodríguez-Vicente, ... Blood Cancer Journal 11 (7), 127, 2021 | 18 | 2021 |
| Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia M Quijada‐Álamo, C Pérez‐Carretero, M Hernández‐Sánchez, ... Clinical and Translational Medicine 11 (2), e304, 2021 | 12 | 2021 |
| Prognosis assessment of early-stage chronic lymphocytic leukemia: are we ready to predict clinical evolution without a crystal ball? I González-Gascón-y-Marín, C Muñoz-Novas, I Figueroa, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 548-555. e4, 2020 | 10 | 2020 |
| DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains M Hernández-Sánchez, AE Rodríguez-Vicente, IGG y Marín, ... Experimental Hematology 72, 9-13, 2019 | 10 | 2019 |
| TRAF3 alterations are frequent in del‐3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features C Pérez‐Carretero, M Hernández‐Sánchez, T González, ... American Journal of Hematology 97 (7), 903-914, 2022 | 4 | 2022 |
| RPS15 and TP53 co-mutation drives B cell malignancy through altered translation and MYC activation in a murine model C Gutierrez, T Ouspenskaia, D Fu, P Waddicor, A Biran, A Liani, ... Blood 136, 28-29, 2020 | 4 | 2020 |
| The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When I González-Gascón-y-Marín, M Ballesteros-Andrés, S Martínez-Flores, ... Cancers 15 (17), 4391, 2023 | 2 | 2023 |
| CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del (11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition MQ Álamo, M Hernández-Sánchez, JL Ordóñez, VA Pérez, AE Rodriguez, ... Blood 132, 948, 2018 | 2 | 2018 |
| Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia EM Ghia, LZ Rassenti, MY Choi, M Quijada-Alamo, E Chu, GF Widhopf, ... Cancer Research 81 (13_Supplement), 3102-3102, 2021 | 1 | 2021 |
| Biological impact of monoallelic and biallelic birc3 loss in del (11q) chronic lymphocytic leukemia progression MQ Álamo, M Hernandez-Sanchez, AE Rodriguez, CP Carretero, ... Blood 136, 4, 2020 | 1 | 2020 |
| Clinical and Biological Impact of TP53 Alterations in Del (11q) Chronic Lymphocytic Leukemia CP Carretero, MQ Álamo, M Hernandez-Sanchez, AE Rodriguez, ... Blood 136, 6-7, 2020 | 1 | 2020 |
